ACT Capital Management LLC Takes $6.33 Million Position in Celcuity, Inc. $CELC

ACT Capital Management LLC bought a new stake in Celcuity, Inc. (NASDAQ:CELC) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 63,415 shares of the company’s stock, valued at approximately $6,325,000. Celcuity accounts for 5.1% of ACT Capital Management LLC’s portfolio, making the stock its 7th biggest position.

Other institutional investors and hedge funds have also bought and sold shares of the company. EverSource Wealth Advisors LLC lifted its position in Celcuity by 1,329.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after purchasing an additional 319 shares during the period. US Bancorp DE lifted its position in Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after purchasing an additional 143 shares during the period. BNP Paribas Financial Markets lifted its position in Celcuity by 78.9% during the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after purchasing an additional 1,167 shares during the period. Meeder Asset Management Inc. bought a new stake in Celcuity during the fourth quarter worth about $42,000. Finally, Ogorek Anthony Joseph NY ADV lifted its position in Celcuity by 19.7% during the fourth quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock worth $66,000 after purchasing an additional 109 shares during the period. Institutional investors own 63.33% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on CELC. Wall Street Zen cut shares of Celcuity from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Stifel Nicolaus set a $150.00 target price on Celcuity in a research note on Monday, May 4th. Macquarie Infrastructure set a $160.00 target price on Celcuity in a research note on Thursday, May 28th. Wolfe Research reaffirmed an “outperform” rating and issued a $110.00 price objective on shares of Celcuity in a research note on Thursday, March 12th. Finally, HC Wainwright lowered their price objective on Celcuity from $185.00 to $145.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Eleven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Celcuity currently has an average rating of “Moderate Buy” and an average target price of $152.09.

Insider Buying and Selling

In related news, Director David Dalvey sold 25,000 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the transaction, the director directly owned 65,000 shares in the company, valued at $9,144,200. This trade represents a 27.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the transaction, the director owned 6,760 shares in the company, valued at approximately $949,509.60. This represents a 57.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 37,000 shares of company stock worth $5,111,950 over the last 90 days. Company insiders own 13.33% of the company’s stock.

Celcuity Price Performance

Celcuity stock opened at $88.05 on Thursday. The stock has a market capitalization of $4.29 billion, a price-to-earnings ratio of -22.58 and a beta of 0.10. Celcuity, Inc. has a 52-week low of $11.27 and a 52-week high of $151.02. The stock’s 50 day moving average price is $118.29 and its two-hundred day moving average price is $111.04. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.10. On average, equities analysts predict that Celcuity, Inc. will post -3.69 earnings per share for the current year.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.